Investor Presentation

88 Investor presentation First six months of 2022 Novo NordiskⓇ Large patient overlaps between diabetes, obesity, and CVD have guided the focused approach in CVD Population overlap between T2D, obesity and CVD ASCVD + HF ~425m people Type 2 diabetes ~537m Obesity ~764m people LDL-C people Focused approach in CVD Atherosclerosis ခြင်း High cholesterol LDLR recycling Endosome Lysosomal degradation LDLR Inflammation- driven pathogenesis IL-6 之仆 CRP Heart failure Heart failure with preserved ejection fraction (HFPEF) □□ Lowering LDL-C to reduce ASCVD hsCRP as surrogate endpoint Improve outcomes Transthyretin amyloid cardiomyopathy (ATTR-CM) Amyloid-depletion through antibody- mediated phagocytosis T2D: Type 2 diabetes, CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; HF: Heart failure; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein Sources: IDF Diabetes Atlas 2021, internal estimate based on European Cardiovascular Disease Statistics, 2017 edition, WHO obesity and overweight fact sheet, 9 June 2021

View entire presentation